Literature DB >> 19652986

Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values.

Laura Mäkitalo1, Taina Sipponen, Päivi Kärkkäinen, Kaija-Leena Kolho, Ulpu Saarialho-Kere.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) constitute a family of enzymes capable of degrading various extracellular matrices (ECM) and basement membrane components playing a role in ECM turnover. They activate and degrade signaling molecules, such as cytokines and chemokines. MMPs are involved in inflammation and have been implicated in tissue degradation and repair occurring in inflammatory bowel disease. The aim of this study was to investigate the MMP profile of intestinal Crohn's disease (CD) patients before and after immunosuppressive treatment (anti-TNF-alpha agents or corticosteroids and conventional immunosuppressants azathioprine or methotrexate) to learn more about the therapeutic pathways for immunosuppressive agents.
METHODS: Expression of MMP-1, MMP-7, MMP-9, MMP-10, and MMP-26 and tissue inhibitors of metalloproteinases (TIMP)-1 and TIMP-3 was studied by immunohistochemistry in pretreatment and post-treatment tissue samples. Semiquantitative immunohistochemical scores were tested for correlations with fecal and serum inflammation markers as well as endoscopic and clinical disease activity scores.
RESULTS: Neutrophil MMP-9 (p = 0.039) and MMP-26 (p = 0.030) and stromal TIMP-1 (p = 0.041) and TIMP-3 (p = 0.029) decreased along with treatment. However, expression of TIMP-3 by enterocytes tended to increase. Total histological score demonstrated positive correlation with neutrophil MMP-9 (p = 0.000), MMP-26 (p = 0.014), and macrophage TIMP-1 (p = 0.001). Calprotectin followed a similar pattern with stromal MMP-26 (p = 0.011), TIMP-1 (p = 0.000), and TIMP-3 (p = 0.001). Crohn's disease endoscopic index of severity (CDEIS) value correlated positively with macrophage TIMP-1 (p = 0.007) and stromal TIMP-3 (p = 0.005). Epithelial TIMP-3 presented with negative correlations with CDEIS (p = 0.006) and C-reactive protein values (p = 0.004).
CONCLUSIONS: Our results suggest that immunosuppressive drugs modulate disease activity in CD by downregulation of MMP-9 and MMP-26 positive neutrophils and stromal TIMP-1 and TIMP-3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19652986     DOI: 10.1007/s00384-009-0756-5

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  47 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

Review 2.  The autonomic nervous system and inflammatory bowel disease.

Authors:  Cormac T Taylor; Stephen J Keely
Journal:  Auton Neurosci       Date:  2007-01-17       Impact factor: 3.145

3.  Matrix metalloproteinase levels are elevated in inflammatory bowel disease.

Authors:  M D Baugh; M J Perry; A P Hollander; D R Davies; S S Cross; A J Lobo; C J Taylor; G S Evans
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine.

Authors:  C J Bailey; R M Hembry; A Alexander; M H Irving; M E Grant; C A Shuttleworth
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

5.  Calprotectin inhibits matrix metalloproteinases by sequestration of zinc.

Authors:  B Isaksen; M K Fagerhol
Journal:  Mol Pathol       Date:  2001-10

6.  Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas.

Authors:  Tiina T Kuivanen; Leila Jeskanen; Lauri Kyllönen; Ulla Impola; Ulpu K Saarialho-Kere
Journal:  Mod Pathol       Date:  2006-05-12       Impact factor: 7.842

7.  Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease.

Authors:  Kaija-Leena Kolho; Taneli Raivio; Harry Lindahl; Erkki Savilahti
Journal:  Scand J Gastroenterol       Date:  2006-06       Impact factor: 2.423

8.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

Review 9.  Review article: Crohn's disease: monitoring disease activity.

Authors:  R Sostegni; M Daperno; N Scaglione; A Lavagna; R Rocca; A Pera
Journal:  Aliment Pharmacol Ther       Date:  2003-06       Impact factor: 8.171

10.  Expression of MMP-9, MMP-10 and TNF-alpha and lack of epithelial MMP-1 and MMP-26 characterize pyoderma gangrenosum.

Authors:  Ville Bister; Laura Mäkitalo; Leila Jeskanen; Ulpu Saarialho-Kere
Journal:  J Cutan Pathol       Date:  2007-12       Impact factor: 1.587

View more
  17 in total

1.  Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease.

Authors:  Kaija-Leena Kolho; Taina Sipponen; Elsa Valtonen; Erkki Savilahti
Journal:  Int J Colorectal Dis       Date:  2014-01       Impact factor: 2.571

2.  Matrix metalloproteinase-10 plays an active role in microvascular complications in type 1 diabetic patients.

Authors:  Marta Toni; José Hermida; María J Goñi; Patricia Fernández; William C Parks; Estefanía Toledo; Ramón Montes; Nieves Díez
Journal:  Diabetologia       Date:  2013-12       Impact factor: 10.122

3.  Low trypsinogen-1 expression in pediatric ulcerative colitis patients who undergo surgery.

Authors:  Maija Piekkala; Jaana Hagström; Maarit Tanskanen; Risto Rintala; Caj Haglund; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

Review 4.  Pathobiology of neutrophil-epithelial interactions.

Authors:  Jennifer C Brazil; Charles A Parkos
Journal:  Immunol Rev       Date:  2016-09       Impact factor: 12.988

5.  Serum immune-activation potency and response to anti-TNF-α therapy in Crohn's disease.

Authors:  Hanne Rintamäki; Taina Sipponen; Harri-M Salo; Outi Vaarala; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

6.  Iatrogenic extracellular matrix disruption as a local trigger for postoperative ileus.

Authors:  Johannes Chang; Sven Wehner; Nico Schäfer; Maria Sioutis; Stephan Bortscher; Andreas Hirner; Jörg C Kalff; Anthony J Bauer; Marcus Overhaus
Journal:  J Surg Res       Date:  2012-06-01       Impact factor: 2.192

7.  Matrix metalloproteinases in the restorative proctocolectomy pouch of pediatric ulcerative colitis.

Authors:  Laura Mäkitalo; Maija Piekkala; Merja Ashorn; Mikko Pakarinen; Antti Koivusalo; Riitta Karikoski; Johanna Natunen; Ulpu Saarialho-Kere; Risto Rintala; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

Review 8.  Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.

Authors:  Emilio G Quetglas; Zlatan Mujagic; Simone Wigge; Daniel Keszthelyi; Sebastian Wachten; Ad Masclee; Walter Reinisch
Journal:  World J Gastroenterol       Date:  2015-11-28       Impact factor: 5.742

Review 9.  Mechanisms that mediate the development of fibrosis in patients with Crohn's disease.

Authors:  Chao Li; John F Kuemmerle
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 10.  Matrix metalloproteinases in inflammatory bowel disease: an update.

Authors:  Shane O'Sullivan; John F Gilmer; Carlos Medina
Journal:  Mediators Inflamm       Date:  2015-04-08       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.